Anzeige
Mehr »
Sonntag, 01.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
394 Leser
Artikel bewerten:
(1)

Peter A. Fields, MD, DC Offers "Gold Standard" in Stem Cell Therapy

Non-Surgical Approach Shows More Benefits to Patients Than Traditional Methods

SANTA MONICA, CA / ACCESSWIRE / January 4, 2021 / Those looking for faster, more effective regeneration of their joints or spine can look to the "Gold Standard" in Stem Cell Therapy offered by Peter A. Fields, MD, DC, who serves as the director of OrthoRegen® in Santa Monica.

The procedure combines four Regenerative Orthopedic procedures, compared with only one or two at other clinics, that incorporate the use of a patient's own stem cells from both fat and bone marrow, along with Platelet Rich Plasma (PRP) and Dextrose Prolotherapy.

The stem cells are autologous or obtained from the patient. This is important, since many other clinics use purchased stem cells or embryonic stem cells that go through a process that actually kills the cells. At OrthoRegen®, we prepare your own cells with a special centrifuge, and concentrate the solution to produce the highest possible number of regenerative cells.

The PRP is also obtained from the patient's own blood. And PRP is full of growth factors that help to speed up recovery further. Additionally, Dextrose Prolotherapy given. This added treatment is especially beneficial in repairing ligaments and tendons to allow for a comprehensive treatment that results in pain relief and improved joint movement.

The Gold Standard in Stem Cell Therapy achieves desirable results without the need for invasive surgery, even if a patient has been told they need a joint replaced.

"Resorting to surgery to repair damaged joints can mean a long recovery time, not to mention dealing with the pain associated with it," says Peter A. Fields, MD, DC. "Once surgery is done, it can never be undone!"

"This approach only requires a handful of treatments for many of our patients, meaning you could see positive results faster than you would imagine."

Stem Cell Therapy enhances the joint's ability to heal itself by stimulating the production of cells, which also includes the regeneration of cartilage. The Gold Standard in Stem Cell Therapy is ideal for those who have been told their joint is "bone on bone", with cartilage damage, and for those whom joint replacement has been recommended.

For more information about the Gold Standard in Stem Cell Therapy, contact OrthoRegen® at 310-453-1234 or visit drfields.com.

About Peter A. Fields, MD, DC
Peter A. Fields, MD, DC, is known as The Athletic Doc®. He is a leading expert in Regenerative Orthopedics, including Stem Cell Therapy, and has appeared on national television. He has served as a clinical instructor with the Hackett-Hemwall-Patterson Foundation. Dr. Fields has completed 11 Ironman triathlons as well as many other shorter distance competitions. Having received treatment to his back and shoulder, Dr. Fields has benefitted himself from these regenerative therapies and has avoided surgery. Peter A. Fields, MD, DC has the distinction of being one of the only physicians in the U.S. that is both a Medical Physician and a Chiropractor, giving him unique credentials and knowledge to benefit his patients.

CONTACT:
Patient Care Coordinator
pcc@drfields.com
310-453-1234

SOURCE: Peter A. Fields, MD



View source version on accesswire.com:
https://www.accesswire.com/623045/Peter-A-Fields-MD-DC-Offers-Gold-Standard-in-Stem-Cell-Therapy

© 2021 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.